Data / Drug companies / HER2/neu Receptor Antagonist
HER2/neu Receptor Antagonist drugs: 9 drugs from 10 companies in the FDA NDC directory
HER2/neu Receptor Antagonist is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 17 products in this class from 10 companies, covering 9 drugs by generic name. The main marketing category is biologics (BLA), and the newest product started marketing on January 1, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 10Companies
- 17Products
- 9Drugs by generic name
Drugs in the HER2/neu Receptor Antagonist class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Trastuzumab | 4 | 4 |
| Margetuximab-cmkb | 2 | 2 |
| Pertuzumab, trastuzumab, and hyaluronidase-zzxf | 2 | 1 |
| Trastuzumab-anns | 2 | 1 |
| Trastuzumab-dkst | 2 | 1 |
| Trastuzumab-strf | 2 | 1 |
| Pertuzumab | 1 | 1 |
| Trastuzumab and hyaluronidase-oysk | 1 | 1 |
| Trastuzumab-qyyp | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Genentech, Inc. | 5 | injection, solution; injection, powder, lyophilized, for solution | Biologics (BLA) | June 29, 2020 |
| Accord BioPharma Inc. | 2 | injection, powder, lyophilized, for solution | Biologics (BLA) | January 1, 2025 |
| Amgen, Inc | 2 | injection, powder, lyophilized, for solution | Biologics (BLA) | October 28, 2019 |
| Biocon Biologics Inc. | 2 | injection, powder, lyophilized, for solution | Biologics (BLA) | October 1, 2023 |
| Cephalon, LLC | 1 | injection, powder, lyophilized, for solution | Biologics (BLA) | March 16, 2020 |
| MacroGenics, Inc | 1 | injection, solution, concentrate | Biologics (BLA) | January 15, 2021 |
| Mylan Institutional LLC | 1 | injection, powder, lyophilized, for solution | Biologics (BLA) | November 29, 2019 |
| Organon LLC | 1 | injection, powder, lyophilized, for solution | Biologics (BLA) | June 1, 2021 |
| Pfizer Laboratories Div Pfizer Inc | 1 | injection, powder, lyophilized, for solution | Biologics (BLA) | March 10, 2021 |
| TerSera Therapeutics LLC | 1 | injection, solution, concentrate | Biologics (BLA) | January 15, 2021 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, powder, lyophilized, for solution | 11 | 64.7% |
| Injection, solution, concentrate | 3 | 17.6% |
| Injection, solution | 3 | 17.6% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.